Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Real-time Boerse Muenchen 02:44:13 2025-09-25 EDT			5-day change	1st Jan Change
0.0985 ^EUR	-0.51%		-.--%	-

09-01	CARMAT SAS Publishes Results Of EFICAS Clinical Study On Aeson Total Artificial Heart As Bridge-To-Transplant Therapy	CI
01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris

Market Cap	6.15M 7.15M 5.8M 5.28M 9.88M 683M 9.96M 69.06M 26.58M 347M 26.84M 26.25M 1.1B	P/E 2023	-3.09x	P/E 2024	-0.95x
Enterprise Value	59.25M 68.89M 55.9M 50.92M 95.2M 6.59B 96.06M 666M 256M 3.34B 259M 253M 10.61B	EV / Sales 2023	56.1x	EV / Sales 2024	13.5x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

09-01	CARMAT SAS Publishes Results Of EFICAS Clinical Study On Aeson Total Artificial Heart As Bridge-To-Transplant Therapy	CI
01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today
01-06	Carmat, GTT, Genfit, LDC... Stocks to Watch Tomorrow in Paris
01-06	Carmat Announces Liquidation and Delisting
12-02	Only Takeover Bid for Carmat Approved by Court
12-02	Carmat: Takeover Offer Approved, 88 Jobs Saved	RE
12-02	Carmat receives takeover bid	RE
11-04	Carmat SAS submits bid for Carmat SA within ongoing receivership procedure	RE
25-10-15	CAC 40 Surges on LVMH Results and Easing US-China Tensions
25-10-15	Carmat: Judicial Recovery Continues, New Hearing Set for November 25	RE
25-10-15	Carmat says liquidation review postponed until Nov 25	RE
25-10-01	Carmat: Judicial Liquidation Request to Be Reviewed on October 14	RE

25-05-09	Carmat: Invest Securities raises target price
25-04-11	Carmat: Invest Securities still a buyer, but cuts TP
25-02-04	Carmat: Invest Securities slightly lowers its target
25-01-09	Carmat: Invest Securities upgrades to buy
25-01-09	Carmat: Oddo BHF reduces its price target

CARMAT Stock Boerse Muenchen

Stocks

CXT

FR0010907956

Medical Equipment, Supplies & Distribution

Valuation : CARMAT

Chart: CARMAT

Latest news : CARMAT

Analysts' recommendations : CARMAT

Press Releases : CARMAT

News in other languages : CARMAT

Quotes and Performance

Managers and Directors : CARMAT

Medical Devices & Implants

Financials

Company Profile

12-02	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
11-04	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
25-10-29	CARMAT : Inside Information / Other news releases	PU
25-10-29	CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025)	BU
25-10-15	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU

03-04	Carmat, Ynsect… quand les pépites industrielles françaises tombent dans le gouffre de Moore
01-07	Pluxee N : Carmat, Hoffmann, LDC, Pluxee, Technip Energies... les valeurs à suivre aujourd'hui à Paris
01-07	Bourse : GTT et Technip Energy engrangent, Pluxee publie, Carmat disparaît
01-07	CARMAT : A suivre aujourd'hui
01-07	Les records continuent à tomber en bourse

Manager	Title	Age	Since
Stéphane Piat CEO	Chief Executive Officer	55	2016-08-31
Pascale d’Arbonneau DFI	Director of Finance/CFO	-	2018-12-11
Christian Latrémouille CTO	Chief Tech/Sci/R&D Officer	-	2025-03-31

Director	Title	Age	Since
Stéphane Piat BRD	Director/Board Member	55	-
Jean-Luc Lemercier BRD	Director/Board Member	68	2017-01-01
Michael Mack BRD	Director/Board Member	79	2017-04-19

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARMAT	-0.51%	-.--%	-	-	7.08M
STRYKER CORPORATION	-0.70%	-11.63%	-31.10%	-10.62%	104B
SMITH & NEPHEW PLC	-1.66%	-5.22%	-29.15%	-5.53%	11.67B
GLAUKOS CORPORATION	+0.04%	-4.55%	+93.67%	+122.98%	10.04B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-1.34%	-3.93%	-55.03%	-71.49%	3.99B
DOUBLE MEDICAL TECHNOLOGY INC.	-2.84%	-6.02%	-30.57%	+30.74%	2.4B
INSPIRE MEDICAL SYSTEMS, INC.	+4.87%	+12.72%	-14.12%	-68.19%	1.97B
INSIGHT LIFETECH CO., LTD.	+1.47%	-6.79%	-	-	1.81B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-2.10%	-3.88%	-24.51%	-29.82%	1.53B
Average	-0.30%	-3.81%	-12.97%	-4.56%	17.12B
Weighted average by Cap.	-0.69%	-10.17%	-22.04%	-2.37%

	2023	2024
Net sales	3.84M 4.46M 3.62M 3.3M 6.17M 427M 6.22M 43.12M 16.59M 216M 16.75M 16.39M 687M	7.34M 8.54M 6.93M 6.31M 11.8M 816M 11.91M 82.52M 31.76M 414M 32.07M 31.37M 1.32B
Net income	-53.87M -62.64M -50.83M -46.3M -86.56M -5.99B -87.34M -605M -233M -3.04B -235M -230M -9.65B	-51.4M -59.76M -48.49M -44.18M -82.58M -5.71B -83.33M -578M -222M -2.9B -224M -220M -9.21B
Net Debt	49.64M 57.72M 46.83M 42.66M 79.76M 5.52B 80.48M 558M 215M 2.8B 217M 212M 8.89B	53.1M 61.74M 50.1M 45.64M 85.32M 5.9B 86.1M 597M 230M 2.99B 232M 227M 9.51B